Perspectives

An update on GLP-1 agonists: where do they fit in the type 2 diabetes management algorithm?

Timothy M.E. Davis

Figures

© RFBSIP/STOCK.ADOBE.COM model used for illustrative purposes only
© RFBSIP/STOCK.ADOBE.COM model used for illustrative purposes only

Abstract

The cardiometabolic and renal benefits of glucagon-like peptide-1 agonists, and their relatively good safety profile, have rightly positioned them as a candidate for combination therapy in people with type 2 diabetes after metformin in most contemporary management algorithms.

Key Points

  • Glucagon-like peptide-1 (GLP-1) agonists are injectable therapies that exploit endogenous hormonal blood glucose control for people with diabetes.
  • GLP-1 agonists have body weight and blood pressure benefits in addition to lowering blood glucose concentrations.
  • Some of the analogues in the class have shown reductions in cardiovascular disease and renal benefits in placebo-controlled intervention trials.
  • There have been no safety concerns in the intervention trials using GLP-1 agonists, but upper gastrointestinal side effects may limit tolerability in some patients.

Figures

© RFBSIP/STOCK.ADOBE.COM model used for illustrative purposes only
© RFBSIP/STOCK.ADOBE.COM model used for illustrative purposes only